Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for hospitalized COVID-19 patients in Iran
IRCT20081027001411N4Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of tocilizumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Radiographic features findings, Mortality rate and 3 more. Started Apr 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20081027001411N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20081027001411N4.